Literature DB >> 34850277

Use of ascitic CEA levels as a predictive value for distant metastasis in high-risk stage II and III colorectal cancer.

Abdullah Al-Sawat1, Jung Hoon Bea2, Seung-Rim Han2, Hyo Jin Lee2, Mi Ran Yoon2, Yoon Suk Lee2, Do Sang Lee2, Chul Seung Lee3, In Kyu Lee2.   

Abstract

PURPOSE: This study aimed to analyze the effect of ascitic carcinoembryonic antigen (CEA) levels on the long-term oncologic outcomes of colorectal cancer (CRC) following curative treatment.
METHODS: A total of 191 patients with stage II/III CRC were included. CEA was analyzed on the peritoneal fluid samples taken at the start of each surgery. Long-term oncologic outcomes were analyzed using known risk factors for recurrence in CRC. RESULT: Multivariate analysis of recurrence showed that lymphatic invasion (hazards ratio (HR) 2.7, 95% confidence interval (CI) 1.1-7, p = 0.038), vascular invasion (HR 2.8, 95% CI 1.2-6.3, p = 0.013), mucinous cancer (HR 3.6, 95% CI 1.3-10.1, p = 0.017), and peritoneal fluid CEA exceeding 5 ng/dl (odds ratio 3.1, 95% CI 1.2-7.7, p = 0.017) were significant risk factors. There were 14 patients with liver metastasis, 11 of whom had high ascitic CEA levels and no peritoneal metastasis. Additionally, eight had lung metastasis, and seven of them had high ascitic CEA levels.
CONCLUSION: High ascitic CEA levels showed significantly lower disease-free survival and were significantly associated with distant metastasis in the lung and liver.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Ascites; Carcinoembryonic antigen; Colonic neoplasms; Risk factors

Mesh:

Substances:

Year:  2021        PMID: 34850277     DOI: 10.1007/s00384-021-04070-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  1 in total

1.  Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer--can monoclonal antibodies do better?

Authors:  N S Ambrose; F MacDonald; J Young; H Thompson; M R Keighley
Journal:  Eur J Surg Oncol       Date:  1989-04       Impact factor: 4.424

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.